1Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and - the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia [ J]. Urologe A ,2002,41:412-424.
2Peters DH ,Sorkin EM. Finasteride : a review of its potential in the treatment of benign prostatic hyperplasia [ J]. Drugs,1993,46 : 177-208.
3Vermeulen A, Giagulli VA, de-Schepper P, et al. Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reduetase in humans [ J]. Prostate, 1989,14:45-53.
4Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-( 2-methyl-2-propyl ) -3-oxo-4-aza-5α-andros-I -ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α- reductase,in volunteers [ J]. Eur J Drug Metab Pharmacokinet, 1991,16 : 15-21.
5Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α- reductase inhibitor, on circulating androgens in male volunteers [ J]. J Clin Endocrinol Metab,1990,70 : 1136-1141.
6McConnell JD,Wilson JD, George FW, et al. Finasteride , an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia [ J ]. J Clin Endocrinol Metab, 1992,74:505-508.
7Norman RW, Coakes KE ,Wright AS ,et al. Androgen metabolism in receiving finasteride before prostatectomy [ J ]. J Urol, 1993,150 : 1736-1739.
8Geller J. Effect of finastefide, a 5α- reductase inhibitor, on prostate tissue androgens and prostate-specific antigen [J]. J Clin Endocrinol Metab, 1990,71 : 1552-1555.
9Guess HA, Heyse JF,Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia [ J]. Prostate, 1993,22:31-37.
2Carlin BI, Boder DR, Spirnak JP, et al. Role of finasteride in the treatment of recurrent heamaturia secondary to benign prostatic hyperplasia. Prostate, 1997,31 : 180-182.
3Foley SJ,Soloman LZ, Wedderburn AW .et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Uro1,2000,163:436-438.
4Vemeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors:an international consensus on the methodology and criteria of evaluation. Eur J Cancer, 1996,32A : 2474-2484.
5Hahn RG. Dextran 70 and blood loss during transurethral resection of the prostate. Acta Anaes Scand, 1996,40 ;820-823.
6Lekas JM, Widmark BA, Damber JE. Decrement of blood flow preceeds the involution of the ventral prostate in the rat after castration.Urol Res, 1997,25:309-314.
7Takeshita S, Lu Hang, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest, 1994,93:662-665.
8Leung D, Cachianes G, Kuarg W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989,246: 1306-1301.
9Yamamoto S,Konishi I, Tsuruta Y, et al. Expression of vascular endothelial growth factor (VEGF) during folliculegenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol, 1997,11 :371-381.
10Haggstrom S,Wikstrom P, Bergh A, et al. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.Prostate, 1998,36:71-79.
8Constanzer ML, Chavez CM, Matuszewski BK. Picogram determination finasteride in human plasma and semen by high- performance chromatography with atmospheric -pressure chemical -ionization tandem spectrometry [J]. Journal of chromatography B, 1994,658 : 281.
9Temkazu Takano, Shunstrke Ham. high - performance liquid chromatographic determination of finasteride in human plasma using direct injection with column switching[J]. Journal of chromatography B, 1996,676:141.
10MeConnell JD,Bruskewitz R,Walsh P,et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. [ J ]. N Engl Med, 1998,338 ( 9 ) : 557.
